Get the Stockscreener App
4.0274
2.92%
-0.1326
Replimune Group Inc stock is traded at $4.0274, with a volume of 1.23M.
It is down -2.92% in the last 24 hours and down -26.44% over the past month.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.
See More
Previous Close:
$4.16
Open:
$4.1
24h Volume:
1.23M
Relative Volume:
0.14
Market Cap:
$314.96M
Revenue:
-
Net Income/Loss:
$-209.96M
P/E Ratio:
-1.2745
EPS:
-3.16
Net Cash Flow:
$-176.27M
1W Performance:
+16.73%
1M Performance:
-26.44%
6M Performance:
-62.22%
1Y Performance:
-63.52%
1-Day Range:
$4.00
$4.11
1-Week Range:
$3.12
$4.39
52-Week Range:
$2.68
$17.00
Replimune Group Inc Stock (REPL) Company Profile
Name
Replimune Group Inc
Sector
Industry
Phone
(781) 222-9600
Address
500 UNICORN PARK, WOBURN, MA
Compare REPL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
REPL
Replimune Group Inc
|
4.035 | 324.71M | 0 | -209.96M | -176.27M | -3.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
380.40 | 96.56B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
447.55 | 60.08B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
553.82 | 61.15B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
709.05 | 44.66B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
328.85 | 36.23B | 3.81B | -644.79M | -669.77M | -6.24 |
Replimune Group Inc Stock (REPL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-19-25 | Downgrade | JP Morgan | Neutral → Underweight |
| Jul-30-25 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Jul-23-25 | Downgrade | BMO Capital Markets | Outperform → Underperform |
| Jul-23-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Jul-23-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jul-22-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-22-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jul-22-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-22-25 | Downgrade | Wedbush | Outperform → Neutral |
| Jun-20-25 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-28-24 | Initiated | ROTH MKM | Buy |
| Apr-17-23 | Resumed | Piper Sandler | Overweight |
| Nov-19-21 | Initiated | Piper Sandler | Overweight |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Nov-17-20 | Initiated | BTIG Research | Buy |
| Nov-02-20 | Initiated | Jefferies | Buy |
| Oct-15-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jul-01-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-05-20 | Initiated | Barclays | Overweight |
| Sep-04-19 | Initiated | ROTH Capital | Buy |
| Jul-23-19 | Initiated | Chardan Capital Markets | Buy |
| Jul-12-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-08-19 | Initiated | H.C. Wainwright | Buy |
| Apr-25-19 | Initiated | Wedbush | Outperform |
| Jan-23-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-14-18 | Initiated | JP Morgan | Overweight |
| Aug-14-18 | Initiated | Leerink Partners | Outperform |
View All
Replimune Group Inc Stock (REPL) Latest News
Join the Replimune Group (REPL) Securities Fraud Lawsuit Investigation - Claim Depot
REPL Stock Plunges 54% in 3 Months After FDA Rejects Skin Cancer Drug - TradingView
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming DeadlinesREPL - PR Newswire
Investigation announced for Long-Term Investors in shares - openPR.com
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune - FinancialContent
Strategies to average down on Replimune Group Inc.Market Movers & Technical Buy Zone Confirmation - newser.com
Replimune’s SWOT analysis: biotech stock faces FDA hurdles amid sector optimism - Investing.com
REPL Deadline: REPL Investors with Losses in Excess of $100K Have Opportunity to Lead Replimune Group, Inc. Securities Lawsuit Filed by The Rosen Law Firm - Morningstar
REPLIMUNE FINAL DEADLINE ALERT: Bragar Eagel & Squire, P.C. - GlobeNewswire
Replimune Group, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before September 22, 2025 to Discuss Your RightsREPL - WV News
Tools to assess Replimune Group Inc.’s risk profilePortfolio Risk Summary & Weekly Breakout Watchlists - newser.com
2025-09-22 | Shareholders of Replimune Group, Inc. (REPL): Protect Your Rights Before September 22, 2025Contact Levi & Korsinsky | NDAQ:REPL | Press Release - Stockhouse
REPL Investors Have Opportunity to Lead Replimune Group, Inc. Se - GuruFocus
REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Fraud Lawsuit with the Schall Law Firm - MarketScreener
Join Class Action to Recover Losses from Replimune Group, Inc. (REPL)Contact Levi & Korsinsky Before September 22, 2025 - Barchart.com
REPL INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
REPL FINAL DEADLINE ALERT: Replimune (REPL) Shares Tank 45% - GlobeNewswire
REPL FINAL DEADLINE ALERT: Replimune (REPL) Shares Tank 45% After Company Says No Pathway Identified For Lead Drug RP1, Securities Class Action Pending - GlobeNewswire Inc.
Levi & Korsinsky Notifies Replimune Group, Inc. (REPL) InvestorsLead Plaintiff Deadline on September 22, 2025 - Stockhouse
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune - GlobeNewswire
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune - GlobeNewswire Inc.
REPL DEADLINE TOMORROW: ROSEN, SKILLED INVESTOR COUNSEL, - GlobeNewswire
2025-09-20 | REPL LAWSUIT ALERT: Levi & Korsinsky Notifies Replimune Group, Inc. InvestorsLead Plaintiff Deadline September 22, 2025 | NDAQ:REPL | Press Release - Stockhouse
REPL Deadline: Rosen Law Firm Encourages Replimune Group, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important September 22 Deadline in Securities Class Action First Filed by the Firm – REPL | FinancialContent - FinancialContent
Replimune (REPL) Shares Tank 45% After Company Says No Pathway Identified For Lead Drug RP1, Securities Class Action PendingHagens Berman - PR Newswire
Replimune: Further Uncertainty Of RP1 Warrants Move To 'Hold' Rating (NASDAQ:REPL) - Seeking Alpha
JPMorgan Chase & Co. Reiterates "Underweight" Rating for Replimune Group (NASDAQ:REPL) - MarketBeat
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune - Newsfile
Class Action Filed Against Replimune Group, Inc. (REPL) Seeking Recovery for Investors – Contact Levi & Korsinsky - GlobeNewswire
Analyzing recovery setups for Replimune Group Inc. investors2025 Technical Patterns & Precise Buy Zone Identification - newser.com
Class Action Filed Against Replimune Group, Inc. (REPL) Seeking Recovery for Investors – ... - Bluefield Daily Telegraph
Why Replimune Stock Was Tumbling Again Today - AOL.com
Replimune (REPL) Stock Dips Amid FDA Meeting and Analyst Downgrade - GuruFocus
Shareholders SueWallSt in New Class Action Against Replimune Group, Inc.Act Now - Nasdaq
Replimune (REPL) Faces Downgrade Amid Regulatory Uncertainty - GuruFocus
Replimune stock downgraded at J.P. Morgan (REPL:NASDAQ) - Seeking Alpha
Replimune Group (REPL) Nosedives 39% as FDA Approval for Melanoma Treatment ‘Uncertain’ - Insider Monkey
REPLIMUNE ALERT: Bragar Eagel & Squire, P.C. Reminds - GlobeNewswire
JP Morgan Downgrades Replimune Group (REPL) to Underweight | REP - GuruFocus
Replimune stock unchanged as H.C. Wainwright maintains Neutral rating - Investing.com
This United Parcel Service Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Friday - Benzinga
BREAKING: Replimune Shares Drop Over 40%; Investors Should - GlobeNewswire
Factset, Metlife, Replimune - TradingView
Replimune stock rating downgraded by JPMorgan on regulatory concerns - Investing.com
Goldman Sachs Group Inc. Acquires 119,145 Shares of Replimune Group, Inc. $REPL - MarketBeat
REPLIMUNE GROUP, INC. (NASDAQ: REPL) SHAREHOLDER ALERT - GlobeNewswire
Why Replimune Stock Plummeted by Almost 40% Today - MSN
Replimune (REPL) Faces Setback After FDA Meeting - GuruFocus
Faruqi & Faruqi Reminds Replimune Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 22, 2025REPL - PR Newswire
REPLIMUNE DEADLINE: ROSEN, THE FIRST FILING FIRM, Encourages Replimune Group, Inc. Investors to Secure Counsel Before Important September 22 Deadline in Securities Class Action First Filed by the FirmREPL - MarketScreener
Replimune Group, Inc. Investors: Please contact the Portnoy - GlobeNewswire
Replimune Group Inc Stock (REPL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Replimune Group Inc Stock (REPL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Astley-Sparke Philip | Director |
May 20 '25 |
Sale |
8.06 |
32,279 |
260,169 |
1,405,071 |
| Xynos Konstantinos | Chief Medical Officer |
May 20 '25 |
Sale |
8.06 |
7,952 |
64,093 |
146,933 |
| Schwendenman Andrew | Chief Accounting Officer |
May 20 '25 |
Sale |
8.05 |
3,287 |
26,460 |
68,284 |
| Patel Sushil | Chief Executive Officer |
May 20 '25 |
Sale |
8.06 |
25,105 |
202,346 |
343,576 |
| Hill Emily Luisa | Chief Financial Officer |
May 20 '25 |
Sale |
8.05 |
2,535 |
20,407 |
143,522 |
| Sarchi Christopher | Chief Commercial Officer |
May 20 '25 |
Sale |
8.05 |
3,749 |
30,179 |
128,296 |
| Patel Sushil | Chief Executive Officer |
Dec 16 '24 |
Sale |
12.42 |
10,000 |
124,200 |
202,014 |
0.88%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):